MediFind

Find a Doctor

Yuichiro Ohe

National Cancer Center Hospital

Bio


Yuichiro Ohe is in Tokyo, Japan. They have been an author on 272 peer reviewed articles and participated in 1 clinical trials in the past 15 years. Dr. Ohe's top three areas of expertise are Non-Small Cell Lung Cancer, Lung Cancer, and EGFR Positive Lung Cancer.

Contact

Tokyo, JP

Latest Research


Latest Advance
Study
  • Condition: Fusion-Positive Non-Small-Cell Lung Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Selpercatinib
  • Number of Patients: 105
  • Published —
In this study, researchers evaluated the outcomes of using selpercatinib for the treatment of fusion-positive non-small-cell lung cancer.
Latest Advance
Study
  • Condition: ?75 Years Old with Squamous-cell Lung Cancer
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Carboplatin plus Weekly Nab-paclitaxel
  • Number of Patients: 46
  • Published —
The study researched the safety and effectiveness of carboplatin plus weekly nab-paclitaxel in patients who are 75 years or older with squamous-cell lung cancer.
Latest Advance
Study
  • Condition: Refractory Immune-Related Thrombocytopenia Induced by Pembrolizumab in Patient with Non-Small Cell Lung Cancer (NSCLC)
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Eltrombopag Olamine
  • Number of Patients: 1
  • Published —
This case report describes a patient with advanced non-small cell lung cancer (NSCLC) complicated by pembrolizumab-induced refractory immune-related thrombocytopenia treated with eltrombopag olamine.
Latest Advance
Study
  • Condition: Non-Small Cell Lung Carcinoma
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Salvage Surgery after Chemotherapy and/or Radiotherapy Including Stereotactic Body Radiation Therapy and Proton Therapy
  • Number of Patients: 38
  • Published —
The study researched the outcomes in salvage surgery after chemotherapy and/or radiotherapy including stereotactic body radiation therapy and proton therapy.
Latest Advance
Study
  • Condition: Non-small-cell Lung Cancer
  • Journal: Cancer science
  • Treatment Used: Nivolumab and Chemotherapy
  • Number of Patients: 24
  • Published —
In this study, researchers evaluated the long-term safety and effectiveness of nivolumab and chemotherapy for the treatment of advanced non-small-cell lung cancer.
Latest Advance
Study
  • Condition: EGFR-Mutant Lung Cancer
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Osimertinib Combined with Selumetinib, Savolitinib, Or Durvalumab
  • Number of Patients: 77
  • Published —
In this study, researchers evaluated the effects of adding osimertinib to selumetinib, savolitinib, or durvalumab for the treatment of EGFR-mutant lung cancer.
Latest Advance
Study
  • Condition: Advanced Non-squamous Non-small Cell Lung Cancer
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Chemoradiotherapy with Cisplatin + S-1 Versus Cisplatin + Pemetrexed
  • Number of Patients: 102
  • Published —
In this study, researchers compared the effectiveness of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
Latest Advance
Study
  • Condition: ROS1 fusion-positive non-small-cell lung cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Entrectinib
  • Number of Patients: 53
  • Published —
The study researched the effects of Entrectinib for ROS1 fusion-positive non-small-cell lung cancer.
Latest Advance
Study
  • Condition: Japanese Patients With Non-Small Cell Lung Cancer
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Nivolumab
  • Number of Patients: 901
  • Published —
This study analyzed the effectiveness of nivolumab treatment for Japanese patients with non-small cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Chemotherapy-induced nausea and vomiting
  • Journal: The Lancet. Oncology
  • Treatment Used: Olanzapine 5 mg plus standard antiemetic therapy
  • Number of Patients: 710
  • Published —
The study researched the effects of Olanzapine 5 mg plus standard antiemetic therapy for chemotherapy-induced nausea and vomiting.
Latest Advance
Study
  • Condition: EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Journal: The New England journal of medicine
  • Treatment Used: Osimertinib
  • Number of Patients: 556
  • Published —
This study reported overall survival for osimertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Immune-Related Pneumonitis with Presence of Preexisting Interstitial Lung Disease (ILD) in Patients with Non-Small Cell Lung Cancer (NSCLC)
  • Journal: Cancer immunology, immunotherapy : CII
  • Treatment Used: Anti-Programmed Cell Death 1 Antibody
  • Number of Patients: 331
  • Published —
This study evaluated the dependence of preexisting interstitial lung disease (ILD) on anti-programmed cell death 1 (PD-1) antibody-induced pneumonitis in patients with non-small cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Severe Neutropenia in Japanese patients with Lung Cancer
  • Journal: Cancer science
  • Treatment Used: Individual Optimal Dose of Amrubicin
  • Number of Patients: 50
  • Published —
This study determined the individual optimal amrubicin doses for Japanese patients with lung cancer after platinum-based treatment.
Latest Advance
Study
  • Condition: Unresectable or Recurrent Thymic Carcinoma (TC)
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Nivolumab
  • Number of Patients: 15
  • Published —
This study evaluated nivolumab for unresectable or recurrent thymic carcinoma.
Latest Advance
Study
  • Condition: Advanced non-small cell lung cancer (NSCLC)
  • Journal: International journal of clinical oncology
  • Treatment Used: EAST-LC trial: S-1 versus docetaxel
  • Number of Patients: 724
  • Published —
This study compared the clinical effectiveness of f S-1 versus docetaxel for Japanese patients with advanced non-small cell lung cancer (NSCLC). Overall survival (OS), progression-free survival (PFS), response rate (RR) quality of life (QOL) and safety were specifically addressed.
Latest Advance
Study
  • Condition: Non–small?cell lung cancer (NSCLC) with anaplastic lymphoma kinase fusion gene?rearrangement .
  • Journal: Cancer science
  • Treatment Used: alectinib
  • Number of Patients: 1251
  • Published —
This study evaluates the safety and effectiveness of alectinib ( a drug used to lower the activity of anapestic lymphoma kinase) in patients with non-small-cell lung cancer (NSCLC) -- a subset of lung cancer.
Latest Advance
Study
  • Condition: Superior sulcus tumour
  • Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • Treatment Used: Trimodality therapy
  • Number of Patients: 60
  • Published —
The study researched the safety and effectiveness of trimodality therapy for treating superior sulcus tumour.
Latest Advance
Study
  • Condition: Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Journal: JAMA oncology
  • Treatment Used: Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression
  • Number of Patients: 0
  • Published —
The purpose of this study was to evaluate the effectiveness and safety of continuous bevacizumab treatment beyond first progression in Advanced Non-Small Cell Lung Cancer (NSCLC).
Latest Advance
Study
  • Condition: Non-small-cell lung cancer
  • Journal: Clinical lung cancer
  • Treatment Used: Chemoradiotherapy
  • Number of Patients: 200
  • Published —
This study evaluated chemoradiotherapy in elderly patients with non-small-cell lung cancer.
Latest Advance
Study
  • Condition: Locally Advanced Non-Small-Cell Lung Cancer (LA-NSCLC)
  • Journal: Cancer chemotherapy and pharmacology
  • Treatment Used: S-1 Plus Cisplatin with Concurrent Thoracic Radiotherapy
  • Number of Patients: 45
  • Published —
This study evaluated the feasibility and effectiveness of S-1 plus cisplatin at the recommended schedule with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).

All Publications
View All


Publication
Study
  • Journal: Journal of clinical and experimental hematopathology : JCEH
  • Published —
COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma.
Publication
Study
  • Journal: The New England journal of medicine
  • Published —
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

Contact

Tokyo, JP

Insurance

Contact them to find out if they accept your insurance plan.